Secondary hyperparathyroidism and chronic kidney disease

Diabetes Spectrum

Volumn 21, Issue 1, 2008, Pages 19-25

  Tomasello, Sarah ^a  

^a RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM; ALUMINUM HYDROXIDE; CALCITRIOL; CALCIUM; CALCIUM ACETATE; CALCIUM CARBONATE; CINACALCET; DOXERCALCIFEROL; ERGOCALCIFEROL; LANTHANUM CARBONATE; PARATHYROID HORMONE; PARICALCITOL; PHOSPHATE BINDING AGENT; PHOSPHORUS; SEVELAMER; VITAMIN D; VITAMIN D RECEPTOR;

ADYNAMIC BONE DISEASE; BONE DISEASE; BONE TURNOVER; CALCIFICATION; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; COMORBIDITY; DIET RESTRICTION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG WITHDRAWAL; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HUMAN; HYPERPHOSPHATEMIA; HYPOCALCEMIA; KIDNEY DYSFUNCTION; MINERAL METABOLISM; OSTEOCLAST; PARATHYROID HORMONE RELEASE; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PATIENT MONITORING; PHOSPHATE METABOLISM; RENAL OSTEODYSTROPHY; REVIEW; SECONDARY HYPERPARATHYROIDISM; VITAMIN D DEFICIENCY;

EID: 40449109633     PISSN: 10409165     EISSN: None     Source Type: Journal    
DOI: 10.2337/diaspect.21.1.19     Document Type: Review

References (33)

1. Haussler MR, Whitfield GK, Haussler CA, Hsieh JC, Thompson PD, Selznick SH, Dominguez CE, Jurutka PW: The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Min Res 13:325-349, 1998
2. Brown AJ: Vitamin D. Am J Physiol 277:157-175, 1999
3. Holick MF: Vitamin D for health and in chronic kidney disease. Sem Dialysis 18:266-275, 2005
4. Malluche HH, Mawad H, Koszewski NJ: Update on vitamin D and its newer analogues: actions and rationale for treatment in chronic renal failure. Kidney Int 62:367-374, 2002
5. Block GA, Port FK: Calcium phosphate metabolism and cardiovascular disease in patients with chronic kidney disease. Sem Dialysis 16:140-147, 2003
6. Friedman EA: Consequences and management of hyperphosphatemia in patients with renal insufficiency. Kidney Int 65 (Suppl.):S1-S7, 2005
7. Qunibi WY: Consequences of hyperphosphatemia in patients with end-stage renal disease (ESRD). Kidney Int 64 (Suppl.):S8-S12, 2004
8. Hernandez JD, Wesseling K, Salusky IB: Role of parathyroid hormone and therapy with active vitamin D sterols in renal osteodystrophy. Sem Dialysis 18:290-295, 2005
9. Cozzolino M, Brancaccio D, Gallieni M, Galassi A, Slatopolsky E, Dusso A: Pathogenesis of parathyroid hyperplasia in renal failure. J Nephrol 18:5-8, 2005
10. Horl WH: The clinical consequences of secondary hyperparathyroidism: focus on clinical outcomes. Nephrol Dialysis Transplant 19 (Suppl. 5):V2-V8, 2004
11. Coen G: Adynamic bone disease: an update and overview. J Nephrol 18:117-122, 2005
12. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342:1478-1483, 2000
13. Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 31:607-617, 1998
14. U.S. Renal Data System: USRDS 2006 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesada, Md., National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2006
15. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15:2208-2218, 2004
16. Tomasello S, Dhupar S, Sherman R: Phosphate binders, K/DOQI guidelines, and compliance: the unfortunate reality. Dialysis Transplant 33:236-242, 2004
17. Cozzolino M, Brancaccio D, Gallieni M, Slatopolsky E: Pathogenesis of vascular calcification in chronic kidney disease. Kidney Int 68:429-436, 2005
18. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, Andress DL: Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 71:31-38, 2007
19. de Francisco ALM: Secondary hyperparathyroidism: review of the disease and its treatment. Clin Ther 26:1976-1993, 2004
20. National Kidney Foundation: Bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 43:S1-S201, 2003
21. Stim JA, Lowe J, Arruda JA, Dunea G: Once weekly intravenous calcitriol suppresses hyperparathyroidism in hemodialysis patients. ASAIO J 41:M693-M698, 1995
22. Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D: Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 63:1483-1490, 2003
23. Andress DL: Vitamin D treatment in chronic kidney disease. Sem Dialysis. 18:315-321, 2005
24. Zisman AL, Ghantous W, Schinleber P, Roberts L, Sprague SM: Inhibition of parathyroid hormone: a dose equivalency study of paricalcitol and doxercalciferol. Am J Nephrol 25:591-595, 2005
25. Drueke TB: Which vitamin D derivative to prescribe for renal patients. Curr Opinion Nephrol Hypertension 14:343-349, 2005
26. Quarles LD: Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism in stage 5 chronic kidney disease. Kidney Int 65 (Suppl.):S24-S28, 2005
27. Joy MS, Kshirsagar AV, Franceschini N: Calcimimetics and the treatment of primary and secondary hyperparathyroidism. Ann Pharmacother 38:1871-1880, 2004
28. Charytan C, Coburn JW, Chonchol M, Herman J, Lien YH, Liu W, Klassen PS, McCary LC, Pichette V: Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis. Am J Kidney Dis 46:58-67, 2005
29. Moe SM, Chertow GM, Coburn JW, Quartes LD, Goodman WG, Block GA, Drueke TB, Cunningham J, Sherrard DJ, McCary LC, Olson KA, Turner SA, Martin KJ: Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 67:760-771, 2005
30. Shahapuni I, Mansour J, Harbouche L, Maouad B, Benyahia M, Rahmouni K, Oprisiu R, Bonne J-F, Monge M, El Esper N, Presne C, Moriniere P, Choukroun G, Fournier A: How do calcimimetics fit into the management of parathyroid hormone, calcium, and phosphate disturbances in dialysis patients? Sem Dialysis 18:226-238, 2005
31. Moe SM, Cunningham J, Bommer J, Adler S, Rosansky SJ, Urena-Torres P, Albizem MB, Guo MD, Zani VJ, Goodman WG, Sprague SM: Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrol Dialysis Transplant 20:2186-2193, 2005
32. Moe SM, Chertow GM, Coburn JW, Quarles LD, Goodman WG, Block GA, Drueke TB, Cunningham J, Sherrard DJ, McCary LC, Olson KA, Turner SA, Martin KJ: Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 67:760-771, 2005
33. Bailie GR, Massry SG, National Kidney Foundation: Clinical practice guidelines for bone metabolism and disease in chronic kidney disease: an overview. Pharmacother 25:1687-1707, 2005